These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12504615)

  • 21. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
    Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
    J Viral Hepat; 2006 May; 13(5):316-21. PubMed ID: 16637862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
    Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
    J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
    [No Abstract]   [Full Text] [Related]  

  • 25. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin.
    Deutsch M; Koskinas J; Tzannos K; Vassilopoulos D; Mailis A; Tolis G; Hadziyannis S
    Ann Pharmacother; 2005 Oct; 39(10):1745-8. PubMed ID: 16159996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two cases of pyogenic spondylitis with chronic hepatitis C during combination therapy of interferon alfa and ribavirin].
    Sugahara K; Saito T; Watanabe H; Misawa K; Ishii R; Suzuki A; Haga H; Sanjo M; Okumoto K; Nishise Y; Ito J; Saito K; Togashi H; Kawata S
    Nihon Shokakibyo Gakkai Zasshi; 2007 Oct; 104(10):1519-25. PubMed ID: 17917401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acute pancreatitis in a hepatitis C positive patient following treatment with peginterferon alfa-2b and ribavirin].
    Kok KF; de Vries RA
    Ned Tijdschr Geneeskd; 2006 Mar; 150(12):681-3. PubMed ID: 16613253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Bini EJ; Mehandru S
    Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    Bhatti A; McGarrity TJ; Gabbay R
    Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
    [No Abstract]   [Full Text] [Related]  

  • 30. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
    Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 32. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.
    Villa F; Rumi MG; Signorelli C; Saibeni S; Del Ninno E; Ferrero Bogetto S; de Franchis R; Vecchi M
    Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1243-5. PubMed ID: 16215439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
    Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.
    Striki A; Manolakopoulos S; Deutsch M; Mela M; Kalafateli M; Schini M; Anagnostou O; Triantos C; Andreadis I; Ketikoglou I; Papatheodoridis G; Pectasides D
    J Viral Hepat; 2014; 21(9):624-32. PubMed ID: 24224747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Roomer R; Hansen BE; Janssen HL; de Knegt RJ
    Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
    Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
    Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases].
    Jia YH; Gao SJ; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of chronic hepatitis C].
    Bell H; Dalgard O; Bjøro K; Hellum KB; Myrvang B
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):926-8. PubMed ID: 12082838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.